Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 147

Similar articles for PubMed (Select 18536014)

1.

Structure, dynamics, and binding thermodynamics of the v-Src SH2 domain: implications for drug design.

Taylor JD, Ababou A, Fawaz RR, Hobbs CJ, Williams MA, Ladbury JE.

Proteins. 2008 Dec;73(4):929-40. doi: 10.1002/prot.22119.

PMID:
18536014
2.

SH2-PLA: a sensitive in-solution approach for quantification of modular domain binding by proximity ligation and real-time PCR.

Thompson CM, Bloom LR, Ogiue-Ikeda M, Machida K.

BMC Biotechnol. 2015 Jun 26;15(1):60. doi: 10.1186/s12896-015-0169-1.

3.

Structural dynamics of the cereblon ligand binding domain.

Hartmann MD, Boichenko I, Coles M, Lupas AN, Hernandez Alvarez B.

PLoS One. 2015 May 29;10(5):e0128342. doi: 10.1371/journal.pone.0128342. eCollection 2015.

4.

Nanomolar inhibitors of the transcription factor STAT5b with high selectivity over STAT5a.

Elumalai N, Berg A, Natarajan K, Scharow A, Berg T.

Angew Chem Int Ed Engl. 2015 Apr 13;54(16):4758-63. doi: 10.1002/anie.201410672. Epub 2015 Feb 20.

5.

Disorder-to-order transition of MAGI-1 PDZ1 C-terminal extension upon peptide binding: thermodynamic and dynamic insights.

Ramírez J, Recht R, Charbonnier S, Ennifar E, Atkinson RA, Travé G, Nominé Y, Kieffer B.

Biochemistry. 2015 Feb 17;54(6):1327-37. doi: 10.1021/bi500845j. Epub 2015 Feb 3.

PMID:
25590897
6.

Tyrosine phosphorylation of the Lyn Src homology 2 (SH2) domain modulates its binding affinity and specificity.

Jin LL, Wybenga-Groot LE, Tong J, Taylor P, Minden MD, Trudel S, McGlade CJ, Moran MF.

Mol Cell Proteomics. 2015 Mar;14(3):695-706. doi: 10.1074/mcp.M114.044404. Epub 2015 Jan 13.

PMID:
25587033
7.

Thermodynamic parameters for binding of some halogenated inhibitors of human protein kinase CK2.

Winiewska M, Makowska M, Maj P, Wielechowska M, Bretner M, Poznański J, Shugar D.

Biochem Biophys Res Commun. 2015 Jan 2;456(1):282-7. doi: 10.1016/j.bbrc.2014.11.072. Epub 2014 Nov 25.

PMID:
25450618
8.

A bicyclic peptide scaffold promotes phosphotyrosine mimicry and cellular uptake.

Quartararo JS, Eshelman MR, Peraro L, Yu H, Baleja JD, Lin YS, Kritzer JA.

Bioorg Med Chem. 2014 Nov 15;22(22):6387-91. doi: 10.1016/j.bmc.2014.09.050. Epub 2014 Oct 2.

PMID:
25438762
9.

Changes in signal transducer and activator of transcription 3 (STAT3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization.

Resetca D, Haftchenary S, Gunning PT, Wilson DJ.

J Biol Chem. 2014 Nov 21;289(47):32538-47. doi: 10.1074/jbc.M114.595454. Epub 2014 Oct 6.

PMID:
25288792
10.

Structure-based inhibition of protein-protein interactions.

Watkins AM, Arora PS.

Eur J Med Chem. 2015 Apr 13;94:480-8. doi: 10.1016/j.ejmech.2014.09.047. Epub 2014 Sep 16.

PMID:
25253637
11.

c-Src binds to the cancer drug Ruxolitinib with an active conformation.

Duan Y, Chen L, Chen Y, Fan XG.

PLoS One. 2014 Sep 8;9(9):e106225. doi: 10.1371/journal.pone.0106225. eCollection 2014.

12.

The development and application of a quantitative peptide microarray based approach to protein interaction domain specificity space.

Engelmann BW, Kim Y, Wang M, Peters B, Rock RS, Nash PD.

Mol Cell Proteomics. 2014 Dec;13(12):3647-62. doi: 10.1074/mcp.O114.038695. Epub 2014 Aug 18.

PMID:
25135669
13.

Dimeric switch of Hakai-truncated monomers during substrate recognition: insights from solution studies and NMR structure.

Mukherjee M, Jing-Song F, Ramachandran S, Guy GR, Sivaraman J.

J Biol Chem. 2014 Sep 12;289(37):25611-23. doi: 10.1074/jbc.M114.592840. Epub 2014 Jul 29.

PMID:
25074933
14.

Synthesis and in Vitro Evaluation of a Peptidomimetic Inhibitor Targeting the Src Homology 2 (SH2) Domain of STAT6.

Morlacchi P, Mandal PK, McMurray JS.

ACS Med Chem Lett. 2013 Dec 4;5(1):69-72. doi: 10.1021/ml4003919. eCollection 2014 Jan 9.

15.

Application of MM-GB/SA and WaterMap to SRC Kinase Inhibitor Potency Prediction.

Kohlmann A, Zhu X, Dalgarno D.

ACS Med Chem Lett. 2012 Jan 6;3(2):94-9. doi: 10.1021/ml200222u. eCollection 2012 Feb 9.

16.

Evaluation of the interaction between phosphohistidine analogues and phosphotyrosine binding domains.

McAllister TE, Horner KA, Webb ME.

Chembiochem. 2014 May 26;15(8):1088-91. doi: 10.1002/cbic.201402090. Epub 2014 Apr 25.

17.

Influence of neighboring groups on the thermodynamics of hydrophobic binding: an added complex facet to the hydrophobic effect.

Nasief NN, Hangauer D.

J Med Chem. 2014 Mar 27;57(6):2315-33. doi: 10.1021/jm401609a. Epub 2014 Mar 18.

PMID:
24479949
18.

Transient domain interactions enhance the affinity of the mitotic regulator Pin1 toward phosphorylated peptide ligands.

Matena A, Sinnen C, van den Boom J, Wilms C, Dybowski JN, Maltaner R, Mueller JW, Link NM, Hoffmann D, Bayer P.

Structure. 2013 Oct 8;21(10):1769-77. doi: 10.1016/j.str.2013.07.016. Epub 2013 Aug 22.

19.

Differential recognition of syk-binding sites by each of the two phosphotyrosine-binding pockets of the Vav SH2 domain.

Chen CH, Piraner D, Gorenstein NM, Geahlen RL, Beth Post C.

Biopolymers. 2013 Nov;99(11):897-907. doi: 10.1002/bip.22371.

20.

¹H, ¹³C and ¹⁵N backbone and side-chain chemical shift assignments of the free and bound forms of the human PTPN11 second SH2 domain.

Rubio L, Huculeci R, Buts L, Vanwetswinkel S, Lenaerts T, van Nuland NA.

Biomol NMR Assign. 2014 Oct;8(2):297-301. doi: 10.1007/s12104-013-9504-4. Epub 2013 Jul 10.

PMID:
23838815
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk